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Order is subject to terms pertaining to toxicant screening, consumer
awareness, and recordkeeping compliance measures
WORCESTER—The Cannabis Control Commission (Commission) has issued
an amended quarantine order for vaporizer devices and products
manufactured by Marijuana Establishments and Medical Marijuana
Treatment Centers in Massachusetts. E ective at 2 p.m. today, the order
permits the sale of devices used to vaporize  ower for adult and medical use
of marijuana, devices designed to vaporize concentrate that do not contain
usable marijuana, and regulated vaporizer products that are manufactured
starting Thursday which pass screens for vitamin E acetate as well as other
contaminants required under the Commission’s testing protocols.
The Commission’s initial quarantine remains in place for all other marijuana
vaporizer products that have been manufactured prior to December 12.
Today’s action modi es a November 12 quarantine order the Commission
issued following a Superior Court ruling concerning the Commonwealth’s
declared vaping public health emergency and investigative  ndings from the
US Centers for Diseases Control and Prevention (CDC) that identi ed vitamin
E acetate as a chemical of concern among people with e-cigarette, or
vaping, product use associated lung injury. On December 6, the Commission
entered into a data-sharing agreement with the Department of Public Health
(DPH) after DPH identi ed licensees that may be linked to probable lung
injury cases in Massachusetts. No case with a con rmed injury has so far
identi ed using vaping products that were purchased from a licensed
Marijuana Establishment or Medical Marijuana Treatment Center.
As part of an ongoing investigation, the Commission continues to test
vaporizer products for the presence of toxicants or contaminants, including
vitamin E acetate and heavy metals. Using validated tests, Independent
Testing Laboratories have not identi ed detectable levels of vitamin E
acetate from 91 initial vaporizer product testing samples that were collected
from unique source production batches from 19 licensees in November. The
Commission is still awaiting the results of 126 additional vaporizer product
test samples collected from unique source production batches from 22
licensees in December.
Based on initial testing results from samples collected in December, the
Commission has determined continued investigation is necessary to
determine whether any vaporizer product samples exceed the heavy metals
threshold established in the Commission’s Protocol for Sampling and
Analysis of Finished Medical Marijuana Products and Marijuana-infused
Products. The Commission’s investigation into existing vaporizer product
toxicants remains ongoing.
Under the amended order, prior to the sale of any new vaporizer products,
licensees will be required to con rm the  nished products do not contain
vitamin E acetate and remain in compliance with the Commission’s testing
protocols after the injection of usable marijuana concentrate. The order also
underscores all licensees’ ability to submit marijuana vaping products to
Independent Testing Laboratories for vitamin E acetate screening or
retesting for toxicants or contaminants while the Commission’s quarantine on
additional marijuana vaping products remains in place.
Going forward, in accordance with new regulations approved by the
Commission in September, licensees that sell marijuana vaping products will
be required to list their active or inactive additives, including the amount
infused or incorporated during the manufacturing process, including
thickening agents, thinning agents, and speci c terpenes. Under the
amended quarantine order, licensees will also be required to disclose that
the patient or consumer may request to inspect a copy of the product’s
associated testing results.
Retailers and dispensaries that sell vaporizer products will be required to
post a conspicuous disclaimer that reads, “This product has been tested
for contaminants, including Vitamin E Acetate, with no adverse  ndings.
WARNING: Vaporizer Products may contain ingredients harmful to health
when inhaled,” and provide an insert with the same language at point of sale.
Additionally, those that sell disposable and reusable vaporizer devices such
as pens will be required to include a written insert that identi es their
manufacturer, battery, and other known components, and discloses the
materials used in their atomizer coil. This information will be required to be
included in product lists posted on the licensee’s website and other third-
party applications as well.
The amended order also mandates additional compliance terms for
licensees that pertain to recordkeeping in the state’s seed-to-sale tracking
system and between licensees that wholesale products.
While the Commission’s quarantine on products manufactured before
December 12 remains ongoing, patients or consumers who are concerned
about a product they bought previously should consult with the Marijuana
Establishment or Medical Marijuana Treatment Center from which it was
purchased. Licensees may be able to provide more information about where
a product was produced, as well as manufacturing details about the
cartridge, battery, atomizer coil, or other components.
The Commission continues to encourage patients who are impacted by the
quarantine to consult with a clinician about alternatives to care.
For more information about the amended quarantine order, contact the
Commission by emailing Commission@CCCMass.com, call 774-415-0200, or
follow the agency on Facebook and Twitter.
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